Join the DDA or

UK patent expiries 2017/2018

Updated patent expiry information published

June 27th 2017

Tagged: DM Zone news Clinical Zone news

By Ailsa Colquhoun

UKMi has published the following list of drugs that are expected to come off patent during 2017/2018.

The information is taken from Prescribing Outlook – New Medicines, a horizon scanning resource for the NHS to help with budget setting, prescribing planning and medicines management.

This edition focuses on anticipated UK availability of new medicines or licence extensions due in 2017 or 2018 organised by BNF category and likely commissioning route.

Those with an anticipated launch in 2017 contain clinical and therapeutic data plus information on predicted launch date, potential target population and estimated impact on service delivery and cost. Those with a predicted 2018 launch date and all chemotherapy agents contain briefer information.  Horizon scanning is a rapidly changing field; for more up to date information click on the generic name hyperlinks to take you to the individual monographs on the SPS website.

Sections on biosimilar developments and patent expiries are also included as well as a list of recently launched medicines with links to relevant guidance and reviews.

Drug BNF 2017 patent expiry date

*= UK patent only, no SPC

Date includes

paediatric

extension

Generic or biosimilar

Available/in development

Telmisartan/hydrochlorothiazide 2.5.5.2 January Yes
Velaglucerase alfa 9.8.1 January
Olmesartan medoxomil 2.5.5.2 February Yes
Bimatoprost 11.6 March Yes
Icatibant 3 March
Valganciclovir 5.3.2.2 March Yes Yes
Caspofungin 5.2.4 April Yes Yes
Entecavir 5.3.3.1 April Yes
Ertapenem 5.1.2.2 April
Melatonin 4.1.1 April
Parecoxib 15.1.4.2 April*
Tramadol/paracetamol 4.7.2 April
Olopatadine 11.4.2 May
Peginterferon alfa 8.2.4 May*
Tegafur/gimeracil/oteracil 8.1.3 May
Travoprost 11.6 May Yes Yes
Nitisinone 9.8.1 June
Dutasteride 6.4.2 July Yes
Etoricoxib 10.1.1 July* Yes
Pregabalin 4.8.1 July* Yes
Bosentan 2.5.1 August Yes Yes
Estradiol/drospirenone 6.4.1.1 August*
Norelgestromin 7.3.1 August
Omalizumab 3.4.2 August
Pegfilgrastim 9.1.6 August Yes
Ivabradine September
Prasugrel 2.9 September
Ezetimibe 2.12 October Yes
Mucophenolate mofetil E/C 8.2.1 October Yes
Pegvisomant 6.5.1 November
Tadalafil 2.5.1/7.4.5 November Yes
Abatacept 10.1.3 December Yes
Retigabine 4.8.1 December
Rosuvastatin calcium 2.12 December Yes Yes
2018
Abiraterone 8.3.4.2 March
Anidulafungin 5.2.4 March
Adalimumab 1.5.3 / 10.1.3 April Yes
Enfuvirtide 5.3.1 April
Everolimus 8.1.5 July
Varicella-zoster vaccine 14.4 July
Human papilloma virus vaccine (Cervarix) 14.4 September
Vardenafil HCl 7.4.5 October*
Aprepitant 4.6 November
Insulin detemir 6.1.1.2 November
Oxycodone/naloxone 4.7.2 December*
Solifenacin succinate 7.4.2 December Yes

Important notes
Expiry dates in the table above take account of any patent extensions afforded by a Supplementary Protection Certificate (SPC) and a paediatric investigation plan, which together can extend a product’s patent – and protection from generic competition – by up to five and a half years.

The table also indicates where a licence for a generic/biosimilar product is in the latter stages of the EU licensing process, or is already available in the EU. However, it does not follow that a generic or biosimilar product will be available in the UK as patent issues vary between countries. Patent legislation is complex and the above table is for guidance only.

Please also note that expected patent expiry dates are subject to change when new extensions (SPC or paediatric) are granted or if a legal decision alters the patent status of a drug. In addition, the expiries listed here only cover the basic manufacturing patent; additional patents on formulations and uses can influence when a generic or biosimilar becomes available commercially.

The DDA cannot be held responsible for any losses resulting from inaccuracies in this table.

 

For all the latest news of the 2019 DDA annual conference...

Learn more